Ahmad Shabanizadeh - Department of Anatomy, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Hajar Dahim - Department of Pathology, Shahid Beheshti Hospital, Isfahan, Iran
Reza Salahshoor - Department of Anatomy, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
Zahra Taghipour - Department of Anatomy, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Mohammad Mohsen Taghavi - Department of Anatomy, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Hamidreza Gafarineveh - Department of Anatomy, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Bahram Eslami - Department of Anatomy, Faculty of Nursing, Kashmar University of Medical Sciences, Kashmar, Iran
Zahra Babazadeh - Department of Anatomy, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Farangis Fatehi - Department of physiology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Background: Ovarian cancer is the leading cause of death among gynecological cancers. Changes in the methylation of BRCA۱ and BRCA۲ may be an effective mechanism for breast and ovarian cancer. This study evaluates the protein expression and methylation status of BRCA۲ in Iranian patients.Methods: We assessed ۶۰ Mullerian-type ovarian cancers by methylation-specific PCR assays and immunohistochemistry.Results: According to methylation status analysis, there were ۷ of ۶۰ (۱۱.۶۶%) methylated cases that had low protein expression.Conclusion: We concluded that changes in the methylation status of BRCA۲ cannot be used as an appropriate biomarker to ascertain the development of ovarian cancer.